Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
92.04(c) 90.56(c) 93.96(c) 96.37(c) 93.9(c) Last
1 143 434 930 173 995 950 937 022 1 175 144 Volume
-0.75% -1.61% +3.75% +2.56% -2.56% Change
More quotes
Financials (USD)
Sales 2020 2 530 M - -
Net income 2020 -334 M - -
Net cash position 2020 1 843 M - -
P/E ratio 2020 -62,0x
Yield 2020 -
Sales 2021 2 868 M - -
Net income 2021 576 M - -
Net cash position 2021 2 490 M - -
P/E ratio 2021 36,0x
Yield 2021 -
Capitalization 20 564 M 20 564 M -
EV / Sales 2020 7,40x
EV / Sales 2021 6,30x
Nbr of Employees 1 456
Free-Float 98,6%
More Financials
Company
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (82.2%); - royalties (14.2%); - income from research and cooperation agreements (3.6%). 
More about the company
Notations Surperformance© of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INCYTE CORPORATION
01/21INCYTE : Study of Squamous Cell Carcinoma of Anal Canal Accepted for Priority Re..
MT
01/21INCYTE : Announces Acceptance and Priority Review of BLA for Retifanlimab as a P..
BU
01/19INCYTE : to Report Fourth Quarter and Year-End 2020 Financial Results
BU
01/13BRIACELL THERAPEUTICS : Announces Presentation at the 2021 Keystone Symposia Con..
AQ
01/12MORPHOSYS : Incyte New Drug Application for Potential Lymphoma Treatment Accepte..
MT
01/12PRESS RELEASE : MorphoSys and Incyte Announce -2-
DJ
01/12INCYTE : and MorphoSys Announce Acceptance by Health Canada of the New Drug Subm..
AQ
01/08Stocks Close at Fresh Highs as Biden Promises 'Trillions of Dollars' in Stimu..
MT
01/07RBC Capital Raises Price Targets on Seven Stocks, Lowers Targets on Four, Ahe..
MT
01/06INCYTE : MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketin..
AQ
01/05MORPHOSYS : Swissmedic Accepts MorphoSys-Incyte Application for B-Cell Lymphoma ..
MT
01/05Swiss Regulator Accepts MorphoSys, Incyte's Marketing Application for Lymphom..
MT
01/05PRESS RELEASE : MorphoSys and Incyte Announce the -2-
DJ
01/05PRESS RELEASE : MorphoSys and Incyte Announce the Acceptance of the Swissmedic M..
DJ
01/04INCYTE CORPORATION : Report
CO
More news
News in other languages on INCYTE CORPORATION
01/13AKTIE IM FOKUS : Morphosys erholt vom Vortagsminus - Zulassung in Kanada
01/12MORPHOSYS : Health Canada nimmt Tafasitamab-Antrag von Morphosys und Incyte an
2020Aktien New York Schluss: Dow geht Puste aus nach Rekord - Nasdaq steigt
2020Aktien New York: Dow geht nach Rekordhoch die Puste aus - Nasdaq stark
2020Novartis essuie un revers avec le ruxolitinib contre la Covid-19
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | MarketScreener
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 107,06 $
Last Close Price 93,90 $
Spread / Highest target 41,6%
Spread / Average Target 14,0%
Spread / Lowest Target -5,22%
EPS Revisions
Managers and Directors
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION10.80%20 564
MODERNA, INC.27.29%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
IQVIA HOLDINGS INC.4.76%36 531
SEAGEN INC.6.08%34 515